Tags: Drug.

Icatibant (trade name Firazyr) is a peptidomimetic drug consisting of ten amino acids which is a selective and specific antagonist of bradykinin B2 receptors. It has been approved by the European Commission for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency.

Icatibant.png
ATC prefix
B06
ATC suffix
AC02
CAS number
130308-48-4
ChEBI
68556
DrugBank
DB06196
FDA UNII code
7PG89G35Q7
IUPAC name
(2S)-2-(3aS7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]34-dihydro-1H-isoquinoline-3-carbonyl]233a45677a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
PubChem
71364

Loading...

This page contains content from the copyrighted Wikipedia article "Icatibant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.